Department of Infectious Diseases, AP-HP, Hôpital Saint Louis, University of Paris Diderot Paris, France.
J Infect Dis. 2013 Sep;208(6):892-7. doi: 10.1093/infdis/jit280. Epub 2013 Jun 24.
Stored plasma specimens from 164 participants in the ANRS 138 trial were analyzed to determine interleukin 6 (IL-6), high-sensitivity C-reactive protein (hsCRP), and D-dimer levels at baseline and weeks 24 and 48. These virologically suppressed, treatment-experienced patients were randomly assigned to undergo an immediate switch (IS) or a deferred switch (DS; at week 24) from an enfuvirtide-based antiretroviral therapy (ART) regimen to a raltegravir-based regimen. At week 24, a significant decrease from baseline was observed in the IS arm, compared with the DS arm, for IL-6 level (-30% vs +10%; P < .002), hsCRP level (-46% vs +15%; P < .0001), and D-dimer level (-40% vs +6%; P < .0001). At week 48, there was a reproducible decrease in levels of all biomarkers in the DS arm.
对 164 名参与 ANRS 138 试验的参与者的储存血浆标本进行了分析，以确定基线时以及第 24 和 48 周时的白细胞介素 6 (IL-6)、高敏 C 反应蛋白 (hsCRP)和 D-二聚体水平。这些病毒学抑制、有治疗经验的患者被随机分配接受立即转换（IS）或延迟转换（DS；在第 24 周），从基于恩夫韦肽的抗逆转录病毒治疗（ART）方案转换为基于雷特格韦的方案。与 DS 组相比，IS 组在第 24 周时 IL-6 水平（-30% 对+10%；P<.002）、hsCRP 水平（-46% 对+15%；P<.0001）和 D-二聚体水平（-40% 对+6%；P<.0001）从基线显著下降。在第 48 周时，DS 组所有生物标志物水平均呈可重复下降。
